v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2018
Jun. 30, 2017
Current assets:    
Cash $ 3,398 $ 8,088
Accounts receivable - trade 181 175
Work in process 0 26
Prepaid expenses and other current assets 407 283
Total Current Assets 3,986 8,572
Fixed assets, net of accumulated depreciation 25,335 25,589
Intangible assets, net of accumulated amortization 1,687 1,823
Security deposit 26 26
Total Assets 31,034 36,010
Current liabilities:    
Accounts payable (related party of $101 and $87 as of March 31, 2018 and June 30, 2017, respectively) 939 749
Accrued expenses (related party of $478 and $650 as of March 31, 2018 and June 30, 2017, respectively) 746 924
Capital lease obligation - current portion 194 183
Deferred revenue 68 157
Total Current Liabilities 1,947 2,013
Capital lease obligation - net of current portion 24,935 25,082
Total Liabilities 26,882 27,095
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Preferred stock - $0.001 par value; 1,000,000 shares authorized; 1 share issued and outstanding as of both March 31, 2018 and June 30, 2017 0 0
Common stock - $0.001 par value; 275,000,000 and 175,000,000 shares authorized as of March 31, 2018 and June 30, 2017, respectively,115,918,510 and 89,118,510 shares issued and outstanding as of March 31, 2018 and June 30, 2017, respectively 116 89
Additional paid-in capital 87,877 80,977
Accumulated other comprehensive loss (29) (29)
Accumulated deficit (83,810) (72,123)
Total iBio, Inc. Stockholders' Equity 4,154 8,914
Noncontrolling interest (2) 1
Total Equity 4,152 8,915
Total Liabilities and Equity $ 31,034 $ 36,010

Source

v3.8.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Revenues $ 78 $ 37 $ 353 $ 247
Operating expenses:        
Research and development (related party of $227, $225, $600 and $670), net of grant income of $0, $44, $44 and $84 966 1,136 2,944 3,005
General and administrative (related party of $186, $191, $573 and $533) 2,605 2,837 7,690 7,657
Total operating expenses 3,571 3,973 10,634 10,662
Operating loss (3,493) (3,936) (10,281) (10,415)
Other income (expense):        
Interest expense (related party of $478, $481, $1,437 and $1,447) (478) (481) (1,437) (1,447)
Interest income 4 8 13 33
Royalty income 4 4 15 20
Total other income (expense) (470) (469) (1,409) (1,394)
Consolidated net loss (3,963) (4,405) (11,690) (11,809)
Net loss attributable to noncontrolling interest 1 492 3 1,606
Net loss attributable to iBio, Inc. (3,962) (3,913) (11,687) (10,203)
Preferred stock dividends (64) (26) (195) (26)
Net loss available to iBio, Inc. $ (4,026) $ (3,939) $ (11,882) $ (10,229)
Comprehensive loss:        
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.03) $ (0.04) $ (0.12) $ (0.11)
Weighted-average common shares outstanding - basic and diluted 115,449 89,109 102,473 89,109

Source

v3.8.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash flows from operating activities:    
Consolidated net loss $ (11,690) $ (11,809)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Share-based compensation 577 713
Amortization of intangible assets 256 264
Depreciation 1,020 987
Changes in operating assets and liabilities:    
Accounts receivable - trade (6) 357
Accounts receivable - unbilled 0 122
Work in process 26 (38)
Prepaid expenses and other current assets (123) (110)
Security deposit 0 3
Accounts payable 102 7
Accrued expenses (178) 37
Deferred revenue (89) 69
Net cash used in operating activities (10,105) (9,398)
Cash flows from investing activities:    
Additions to intangible assets (85) (259)
Purchases of fixed assets (712) (809)
Net cash used in investing activities (797) (1,068)
Cash flows from financing activities:    
Proceeds from sale of common stock 5,621 0
Costs to raise capital (321) 0
Proceeds from additional paid-in capital - preferred stock 1,050 0
Payment of capital lease obligation (136) (126)
Net cash provided by (used in) financing activities 6,214 (126)
Effect of exchange rate changes (2) 0
Net decrease in cash (4,690) (10,592)
Cash - beginning of period 8,088 23,014
Cash - end of period 3,398 12,422
Schedule of non-cash activities:    
Unpaid intangible assets included in accounts payable 42 197
Intangible assets included in accounts payable in prior period, paid in current period 7 0
Fixed assets included in accounts payable in prior period, paid in current period 87 71
Unpaid fixed assets included in accounts payable 141 468
Issuance of preferred stock for acquisition of additional interest in subsidiary 0 12,499
Supplemental cash flow information:    
Cash paid during the period for interest $ 1,439 $ 1,449

Source